EIDD-1931

EIDD-1931 is a ribonucleoside analog with antiviral activity.[1],[2],[3],[4] It inhibits replication of severe acute respiratory syndrome coronavirus (SARS-CoV) in Vero 76 cells, Middle East respiratory syndrome coronavirus (MERS-CoV) in Calu-3 2B4 cells, and SARS-CoV-2 in Vero cells (IC50s =0.1, 0.15 and 0.3 μM, respectively).[3],[4] It also reduces viral titers of Venezuelan equine encephalitis virus (VEEV) TC-83 in infected Vero cells (EC50 = 0.426 μM) and wild-type and remdesivir-resistant strains of the model CoV mouse hepatitis virus (MHV) in infected DBT cells.[2][4] EIDD-1931 (100 and 400 mg/kg twice per day) reduces lung viral titers in mouse models of respiratory syncytial virus (RSV) and H1N1 influenza A virus infection.[1]

Reference:
[1]. Yoon, J.-J., Toots, M., Lee, S., et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 62(8), e00766-00718 (2018).
[2]. Urakova, N., Kuznetsova, V., Crossman, D.K., et al. β-ᴅ-N4-Hydroxycytidine Is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 92(3), e01965-01917 (2018).
[3]. Barnard, D.L., Day, C.W., Bailey, K., et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir. Chem. Chemother. 17(5), 275-784 (2006).
[4]. Sheahan, T.P., Sims, A.C., Zhou, S., et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12:eabb5883, (2020).